---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-225456"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2022-08-19T23:59:59+00:00"
generated_at: "2026-06-23T22:27:53.557850+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Halozyme ups revolver to $575M, repays term loan and revolver with convertible note proceeds

## Summary
- Revolving credit facility increased by $225M to $575M; all other terms unchanged.
- Company repaid entire term loan facility and all outstanding revolver borrowings using proceeds from previously issued convertible notes.
- Amendment included 11 increase lenders: Bank of America, Wells Fargo, JPMorgan, Citibank, Goldman Sachs, Mizuho, Silicon Valley Bank, and others.
- Conditions included pro forma Consolidated Net Leverage Ratio not exceeding 0.25:1.00 less than the permitted level.

## SEC filing metadata
- accession: 0001193125-22-225456
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2022-08-19T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000119312522225456/0001193125-22-225456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000119312522225456/d384340d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-225456
- JSON: https://secwatch.observer/filing/0001193125-22-225456.json
- Plain text: https://secwatch.observer/filing/0001193125-22-225456.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.